[CAS NO. 534605-74-8] TP3011
PRODUCTS SPECIFICATIONS [534605-74-8]
DESCRIPTION [534605-74-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 474.51 |
| Molecular Formula | C26H26N4O5 |
| SMILES | O=C(N1CCCCC)NC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC=C2 |
Summary
TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38 [1] . TP3011 is against cancer cell lines growth with IC 50 s at the range sub-nanomolar in vitro [2] .
IC50 & Target
|
Topoisomerase I |
In Vitro
TP3011 (0-100 nM; 72 hours) (compound 6c) inhibits cell proliferative activities against various human
cancer
cell lines, producing 50% inhibition (IC
50
) of cell growth of 0.85 nM; 8.5 nM; and 8.2 nM in HCT116, QG56, and NCI-H460 (NSCLC) cells, respectively
[2]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | HCT116, QG56, and NCI-H460 (NSCLC) cells |
| Concentration: | 0-100 nM |
| Incubation Time: | 72 hours |
| Result: | Was against human cancer cell lines, such as CRC and NSCLC cell lines. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Anthoney DA, et al. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.BMC Cancer. 2012 Nov 21;12:536.
- [2] Niizuma S, et al. Synthesis of new camptothecin analogs with improved antitumor activities.Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21.